You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Proteolytic Imaging of Remodeling Myocardium

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Screening the Ribosome for New Target Sites

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant An estimated two million Americans suffer from infections caused by multi drug resistant MDR bacteria resulting in a substantial impact on patientsandapos lives and an extraordinary economic burden Due to the arsenal of antibiotic resistance mechanisms that these bacteria present traditional antibiotic therapies are often ineffective New strategies that u ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. SHAPE RNA Bioinformatics for Therapeutics and Translational Research

    SBC: Ribometrix LLC            Topic: 400

    DESCRIPTION provided by applicant Only of the human genome is translated into proteins whereas roughly is transcribed into RNA Complex higher order structures in these RNAs fundamentally affect critical biological processes As examples RNA structures in the ribosome are the targets of many antibiotics structures in the genomes of RNA viruses like HIV and influenza are essential for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Drug Activation of HSF1 for Prevention of Noise-Induced Hearing Loss

    SBC: CHAPERONE THERAPEUTICS, INC.            Topic: NIDCD

    PROJECT SUMMARY The studies proposed here address a significant health issue the high incidence of acquired deafness from noise overstimulation that can result from recreational and workplace related activities and from service in the military Through a robust academic pharma partnership between investigators at the Kresge Hearing Research Institute with long standing interests and expertise in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this STTR is to identify novel small molecule compounds targeting the nitrogen respiration pathway of Pseudomonas aeruginosa This pathway is crucial to the pathogenesis of P aeruginosa in vivo but has not yet been exploited for antimicrobial drug discovery There is a clear need for new treatments to combat P aeruginosa infections Antibiotic re ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Simultaneous kinetic analyses of neuronal connectivities

    SBC: CIENCIA INC            Topic: 101

    DESCRIPTION provided by applicant Aberrant neuronal connectivity is associated with a number of neuropathological and neuropsychiatric diseases disorders Inefficient developmental connectivity misdirected connectivity or disrupted and degenerated connectivity can account for losses of normal neuronal communication and subsequent losses of mental or physical health Altered expression of axon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Dental Adhesives to Prevent Recurrent Caries

    SBC: CuRE Innovations, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Bacterial related marginal decay is the top reason for failure and retreatment of resin based composite restorations RBCs Retreatment of these restorations costs both the patients and insurance companies billions of dollars per year The weak point of the system is the zone known as the hybrid layer where the adhesive bonds the RBC to the dentin There are ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple Myeloma MM is the second most common form of blood cancer and remains an incurable and deadly disease Proteasome inhibitor PI therapy is a cornerstone in the treatment of MM but resistance to this class of agent is an emerging challenge in the clinic New therapeutic approaches that specifically target resistance are needed to maximize responses and ultimate ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government